Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vericel Corp VCEL

Healthcare Biotechnology
Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic... see more

Recent & Breaking News (NDAQ:VCEL)

Vericel to Report Third-Quarter 2018 Financial Results on November 6, 2018

GlobeNewswire October 23, 2018

Vericel to Present at Multiple Upcoming Conferences

GlobeNewswire September 21, 2018

Vericel Announces Appointment of Jonathan Hopper as Chief Medical Officer

GlobeNewswire August 20, 2018

Vericel Reports Record Second Quarter Revenues of $19.0 Million and Raises Full Year 2018 Revenue Guidance

GlobeNewswire August 6, 2018

Vericel to Present at the 38th Annual Canaccord Genuity Growth Conference

GlobeNewswire July 26, 2018

Vericel to Report Second-Quarter 2018 Financial Results on August 6, 2018

GlobeNewswire July 23, 2018

Rise of Chronic Diseases Leads to Growing Investment in Stem Cell Research

PR Newswire July 11, 2018

Vericel Added to Russell 3000® Index

GlobeNewswire June 25, 2018

Growing Demand for Biotechnologies are Expected to Grow

PR Newswire June 18, 2018

Vericel Corporation Announces Closing of $74.8 Million Public Offering and Full Exercise of The Underwriters’ Option to Purchase Additional Shares

GlobeNewswire June 5, 2018

Vericel Corporation Prices $65 Million Public Offering of Common Stock

GlobeNewswire May 31, 2018

The Stem Cell Market is Projected to Grow Due to Technological Advancements

PR Newswire May 31, 2018

Vericel Corporation Announces Proposed Public Offering of Common Stock

GlobeNewswire May 30, 2018

Vericel to Present at the Jefferies 2018 Global Healthcare Conference

GlobeNewswire May 25, 2018

Vericel Reports First Quarter 2018 Financial Results

GlobeNewswire May 8, 2018

Vericel to Present at the 6th Annual Cell & Gene Therapy Investor Day

GlobeNewswire April 10, 2018

Vericel Reports Publication of Results from the Phase 3 SUMMIT Extension Study Demonstrating Sustained Clinical Benefit of MACI Out to Five Years

GlobeNewswire March 23, 2018

Vericel to Present at the 17th Annual Needham Healthcare Conference

GlobeNewswire March 13, 2018

Vericel to Present at BioCentury’s 25th Annual Future Leaders in the Biotech Industry Conference

GlobeNewswire March 9, 2018

Mid-Day Market Update: Vericel Surges After Strong Q4 Results; Smith Micro Software Shares Fall

Benzinga.com  March 5, 2018